Dec 17, 2019 1:06 pm EST Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering
Dec 9, 2019 5:30 am EST Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program
Nov 6, 2019 6:30 am EST Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program
Oct 31, 2019 5:30 am EDT Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019
Oct 24, 2019 5:30 am EDT Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
Sep 13, 2019 5:30 am EDT Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Sep 5, 2019 5:30 am EDT Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial
Sep 4, 2019 5:30 am EDT Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
